Le Lézard
Classified in: Ebola virus, Health
Subjects: NPT, PER

TB Alliance Welcomes Ariel Pablos-Méndez to Its Board of Directors

NEW YORK, Nov. 6, 2017 /PRNewswire-USNewswire/ -- TB Alliance today announced the appointment of Dr. Ariel Pablos-Méndez to its board of directors. As a physician and a leader in global public health, he brings decades of experience in strategies to improve the lives of the poor and most vulnerable people in the world, including spurring the creation of the TB Alliance in 2001.

Ariel Pablos-Méndez

Dr. Pablos-Méndez is currently Professor of Medicine at Columbia University Medical Center in New York. From 2011 to 2016, he led the Global Health program of the United States Agency for International Development (USAID), where he drove the vision to end preventable child and maternal deaths and contributed to catalyzing an AIDS-Free Generation while supporting health systems strengthening, family planning and country ownership through initiatives such as the Global Financing Facility for Every Woman Every Child. He participated in the US response to Ebola and Zika, and championed the Global Virome Project in 2016.

"I am delighted to be joining TB Alliance's Board as the organization advances the development of faster, better cures for TB," said Dr. Pablos-Méndez. "Our slow progress in controlling TB is imperiled by spreading resistance to existing drugs; we need to invest in research and development for more options."

Dr. Pablos-Méndez began his public health career at Columbia University working on the emergence of multi-drug resistant tuberculosis in New York City in 1991. In 1997, he led the Global Surveillance Project on Anti-Tuberculosis Drug Resistance at the World Health Organization (WHO). In both instances, his research and publications brought about significant and successful policy changes.

As program officer of The Rockefeller Foundation from 1998 to 2004, Dr. Pablos-Méndez spearheaded public-private partnerships in R&D for diseases of poverty, including TB Alliance and the foundation's strategy on AIDS treatment in Africa. In 2007, he returned to Rockefeller as managing director and led the foundation's initiative to position universal health coverage on the international agenda. 

"Dr. Pablos-Méndez brings to TB Alliance invaluable experience and expertise in the fight against tuberculosis alongside other major global health issues," said Dr. Mel Spigelman, president and CEO of TB Alliance. "We are excited to have his support as we put science to work toward transforming TB therapy to achieve the vision of the End TB Strategy."

Dr. Pablos-Méndez received his medical degree from the University of Guadalajara in Mexico and his Masters in Public Health from Columbia University, where he has been a faculty member for over 20 years.

About TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB). Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia's Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Germany's Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Irish Aid, Indonesia Health Fund, National Institute of Allergy and Infectious Disease, Netherlands Ministry of Foreign Affairs, UNITAID, United Kingdom Department for International Development, United States Agency for International Development, and the United States Food and Drug Administration. For more information, please visit: www.tballiance.org

For more information, please contact:
CJ Volpe at CJ.Volpe@tballiance.org or +1 973-303-2522


TB Alliance Logo

SOURCE TB Alliance

These press releases may also interest you

23 fév 2018
This news release contains forward-looking information that is subject to the risk factors and assumptions set out under "Caution Regarding Forward-looking Information".  It should be read in conjunction with the Company's audited financial...

21 fév 2018
The Annual General Meeting of shareholders of Telefonaktiebolaget LM Ericsson will be held on Wednesday, March 28, 2018, at 3 p.m. at Kistamässan, Arne Beurlings Torg 5, Kista/Stockholm. The Nomination Committee proposes among other things: Ronnie...

21 fév 2018
NanoViricides, Inc. (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its second quarter of financial year 2018 in a...

19 fév 2018
Though not likely to immediately realize the billion-dollar revenues projected in many sources, molecular point-of-care is here to say, says market researcher Kalorama Information.  The molecular point-of-care market, consisting of systems with...

15 fév 2018
A Notice is given to the Shareholders of Svenska Cellulosa Aktiebolaget SCA ("SCA") of the Annual General Meeting of Shareholders to be held on Friday 23 March 2018, at 10.30 a.m. at Hotell Södra Berget, Sundsvall (registration from 9 a.m.)...

15 fév 2018
Notice is hereby given that the Annual General Meeting of Aktiebolaget SKF will be held at SKF Kristinedal, Byfogdegatan 4, Gothenburg, Sweden, at 13.00 on Tuesday, 27 March 2018. The doors are open from 11.00. Refreshments will be served prior to...

News published on 6 november 2017 at 09:00 and distributed by: